Pharmaceutical industry improvements

Profile A biotechnology company with proprietary technology, Xenometrix helps the pharmaceutical industry improve the effectiveness of drug discovery and development. 

SMB technology is now a mature technology adopted by pharmaceutical industry. The existence of an organized body of knowledge [39, 40] was helpful in optimizing SMB systems and making them acceptable by the industry. The future will require dynamic simulation for systems with small number of columns, e.g., configurations of the type 1-2-2-1 as encountered in some cases and also in view of process control to improve process performance. 

Hotter and Balannec published one of the first real proposals to use SMB as a production tool for the pharmaceutical industry, and thus to scale down a process already used on a production scale [29]. The first commercially available plant (Licosep) SMB system was offered by Separex in 1991 and was exhibited for the first time in June 1991 during the Achema Exhibition. The system consisted of 24 stainless steel columns with adjustable lengths between a few centimeters up to almost 1 meter, HPLC pumps, and mulitpositional valves. To improve the robustness of the system, a rotary valve replaced two-way valves and the pumps were modified. 

TIMS has helped the pharmaceutical industry to improve efficiency in managing business-critical text documents. However, it is still a time-consuming... 

Describe the pressures on the pharmaceutical industry to improve R D performance, with emphasis on the earlier stages of R D where irreversible choices are made... 

With all the technology found in the modern hospital today, the lack of coordination between other parts of health care, the pharmaceutical industry, and the agencies is outdated. A network that connects these parts together will improve patient safety, improve care, speed the development of new treatments, and support new medical breakthroughs. 

Homogeneous catalysis has an important role to play in enantioselective reactions. To improve product safety, the pharmaceutical industry is producing an increasing number of products in enantiomerically pure form. Other important (future) markets include agrochemicals, polymers and fine chemicals. Although the number of practised processes is quite small the potential is high. 

Metabolic and enzyme engineering have received a lot of attention in academic institutions and are now being applied for the optimization of biocatalysts used in the production of a diverse range of products. Engineered microorganisms, even with non-native enzyme activities, are being used for novel products and process improvements for the production of precursors, intermediates and complete compounds, required in the pharmaceutical industry (Chartrain et ai, 2000). 

The pharmaceutical industry has been giving increased attention to homogeneous asymmetric hydrogenation for the synthesis of chiral molecules due to significant improvements in this technology (1). We recendy synthesized a chiral a-amino acid intermediate using Et-DuPhos-Rh catalyst, obtaining enantiomeric pmities (EP) of... 

A lead is variously defined in the pharmaceutical industry as a compound derived from a hit with some degree of in vitro optimization (potency in primary assay, activity in functional and/or cellular assay), optimization of physical properties (solubility, permeability), and optimization of in vitro ADME properties (microsomal stability, CYP inhibition). Moreover, a lead must have established SAR/SPR around these parameters such that continued optimization appears possible. A lead may also have preliminary PK and in vivo animal model data. However, it is the task of the lead optimization chemist to improve PK and in vivo activity to the levels needed for identification of a clinical candidate. 

The objective for Medicinal Chemistry is the identification of the chemical structures for potential new medicines. Eventually, these new medicines will be launched into the market to address unmet medical needs and to improve the quality of life for all human beings. The marketing of new medicines is the lifeblood of the pharmaceutical industry. Due to the broad impact Medicinal Chemistry has in the drug discovery process, it is recognized as a top job for synthetic organic chemists. 

Xencor seeks corporate partnerships for discovering novel proteins for the pharmaceutical industry and proteins with improved traits for the agricultural biotechnology and industrial enzyme markets. 

---